Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/29/2017 | Series C | $76.37MM | $xx.xx | $40.41B | Alexandria Venture Investments, Arch Venture Partners, Fidelity Management & Research Company, Flagship Pioneering, The Alaska Permanent Fund | |
Price per Share
$xx.xx
Shares Outstanding
20,204,100
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Fidelity Management & Research Company, Flagship Pioneering, The Alaska Permanent Fund
|
||||||
01/26/2016 | Series B | $61MM | $xx.xx | $29.6B | Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners & Flagship Pioneering, Fidelity Management & Research | |
Price per Share
$xx.xx
Shares Outstanding
20,333,333
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners & Flagship Pioneering, Fidelity Management & Research
|
||||||
11/25/2015 | Series A | $31MM | $xx.xx | $7.65B | Arch Venture Partners, Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
31,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Flagship Pioneering
|